+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Direct Acting Antivirals Market - Global Forecast 2026-2032- Product Image
Direct Acting Antivirals Market - Global Forecast 2026-2032- Product Image
Sale

Direct Acting Antivirals Market - Global Forecast 2026-2032

  • Report

  • 195 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6127542
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Direct Acting Antivirals Market is projected to reach USD 52.37 Billion in 2026. It is expected to continue growing at a CAGR of 8.13%, reaching USD 84.56 Billion by 2032.

Direct-Acting Antivirals: Executive Overview

Direct-acting antivirals (DAAs) are small-molecule medicines designed to inhibit specific viral proteins and interrupt replication. Their high degree of molecular targeting has reshaped treatment approaches for several chronic and acute viral infections, particularly where sustained virologic response, shorter regimens, and improved tolerability are clinically meaningful outcomes. Adoption is influenced by diagnostic access, treatment guidelines, reimbursement, procurement systems, resistance management, and the availability of quality-assured medicines.

Treatment Access and Delivery Are Reshaping the DAA Landscape

The DAA landscape is shifting from specialist-centered care toward broader, decentralized treatment models. Simplified testing pathways, fixed-duration regimens, primary-care participation, task sharing, and integrated infectious-disease services can reduce barriers between diagnosis and treatment. At the same time, regulatory variation, intellectual-property arrangements, procurement capacity, medicine quality, and continuity of follow-up remain important determinants of real-world impact. Public-health programs increasingly emphasize finding undiagnosed patients, linking them rapidly to care, and confirming treatment response where clinically appropriate.

Artificial Intelligence Strengthens Discovery, Diagnostics, and Care Pathways

Artificial intelligence can contribute across the DAA value chain without replacing clinical judgment. In discovery, machine-learning methods can support target identification, molecular screening, resistance-risk assessment, and optimization of candidate compounds. In care delivery, predictive tools may help prioritize testing, identify patients at risk of treatment interruption, interpret laboratory information, and support adherence programs. Safe deployment requires representative data, transparent validation, privacy safeguards, cybersecurity, monitoring for bias, and regulatory oversight. AI is most useful when embedded within verified clinical workflows and paired with human review.

Regional Insights: Uneven Access Defines Global Progress

North America benefits from advanced diagnostics, specialist capacity, and established reimbursement systems, while affordability and unequal access can still affect underserved populations. Latin America is shaped by public procurement, decentralized services, diagnostic coverage, and differences in national treatment programs. Europe generally combines strong clinical infrastructure with coordinated guideline development, although access and reimbursement vary across countries. The Middle East requires attention to migrant and displaced populations, laboratory capacity, and continuity of care. Africa faces substantial opportunities through simplified testing, generic access, integrated services, and international health programs, alongside persistent diagnostic and health-system constraints. Asia-Pacific is highly diverse, spanning sophisticated research and care systems to settings where diagnosis, affordability, and rural access remain central challenges.

Group Insights: Policy Blocs Influence Access and Coordination

ASEAN countries can benefit from regional cooperation on procurement, laboratory standards, and cross-border continuity of care, while differing health-system capacities require locally adapted implementation. BRICS members bring substantial scientific, manufacturing, and public-health capabilities, but their priorities and regulatory systems are diverse. The European Union supports coordinated evidence generation and health-policy collaboration, although national reimbursement decisions remain important. G7 members influence research, regulatory practice, financing, and global health partnerships. GCC states generally have strong healthcare infrastructure and can advance screening and specialist integration, while migrant-health needs remain relevant. NATO members span varied health systems, making interoperability, preparedness, and continuity of essential medicines important considerations.

Country Insights: National Systems Determine Treatment Reach

Australia and Canada combine strong clinical capabilities with geographically dispersed populations that make remote access and Indigenous-health partnerships important. Brazil and Mexico must align public procurement, decentralized diagnosis, and care continuity across large and diverse territories. China and India have extensive manufacturing and healthcare-system capabilities, while regional variation and broad screening access remain key considerations. France, Germany, Italy, Spain, and the United Kingdom operate mature healthcare systems in which guideline implementation, reimbursement, testing pathways, and elimination-oriented programs shape outcomes. Japan and South Korea bring advanced diagnostics and regulatory capacity, with attention to aging populations and healthcare integration. Russia’s treatment environment is influenced by domestic health policy, diagnostic reach, and supply continuity.

Priorities for Leaders: Link Diagnosis, Treatment, and Equity

Industry leaders should prioritize quality-assured, accessible regimens; invest in heat-stable and simplified formulations where clinically appropriate; and support diagnostic-to-treatment pathways that reduce patient loss between steps. Partnerships with ministries, laboratories, community organizations, and healthcare providers can improve case finding and adherence while respecting local priorities. Evidence generation should address diverse populations, comorbidities, resistance, long-term outcomes, and real-world implementation. Organizations deploying digital or AI tools should establish governance, validation, explainability, and post-deployment monitoring. Leaders should also strengthen supply resilience through diversified sourcing, transparent quality systems, and contingency planning.

Methodology: Evidence-Led Executive Synthesis

This executive summary uses the supplied market scope for direct-acting antivirals and synthesizes established clinical, public-health, regulatory, access, and health-system considerations. Regional, group, and country narratives are organized around documented determinants of treatment availability and outcomes, including diagnosis, procurement, reimbursement, delivery capacity, medicine quality, and continuity of care. No market estimates, market sizing, market shares, forecasts, or company-specific claims are used. Interpretations should be validated against current national guidelines, regulatory decisions, epidemiological data, and program-level evidence before operational use.

Conclusion: Sustainable Impact Depends on Integrated Access

Direct-acting antivirals offer substantial clinical value when patients can be identified, receive appropriate treatment, and remain connected to care. The next phase of progress depends less on pharmacology alone than on integrated diagnostics, equitable financing, reliable supply, competent delivery systems, and responsible use of data and AI. Regional coordination and country-specific implementation will be essential to translate therapeutic advances into durable public-health gains.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Direct Acting Antivirals Market, by Drug Class
7.1. Introduction
7.2. Ns3/4A Protease Inhibitors
7.2.1. Glecaprevir
7.2.2. Voxilaprevir
7.3. Ns5A Inhibitors
7.3.1. Ledipasvir Sofosbuvir
7.3.2. Velpatasvir Sofosbuvir
7.4. Ns5B Polymerase Inhibitors
7.4.1. Dasabuvir
7.4.2. Sofosbuvir
8. Direct Acting Antivirals Market, by Route Of Administration
8.1. Introduction
8.2. Fixed Dose Combinations
8.2.1. Once Daily Dosing
8.2.2. Twice Daily Dosing
8.3. Single Agent Tablets
8.3.1. Once Daily Dosing
8.3.2. Twice Daily Dosing
9. Direct Acting Antivirals Market, by Treatment Regimen
9.1. Introduction
9.2. Combination Therapy
9.2.1. Dual Therapy
9.2.1.1. Ns3 4A Ns5A
9.2.1.2. Ns5A Ns5B
9.2.2. Triple Therapy
9.3. Monotherapy
10. Direct Acting Antivirals Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Direct Acting Antivirals Market, by End User
11.1. Introduction
11.2. Hospitals
11.3. Retail Pharmacies
11.4. Specialty Clinics
12. Direct Acting Antivirals Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Direct Acting Antivirals Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Direct Acting Antivirals Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Amgen Inc.
16.3. AstraZeneca plc
16.4. Aurobindo Pharma Limited
16.5. Bayer AG
16.6. Biogen Inc.
16.7. Boehringer Ingelheim International GmbH
16.8. Bristol-Myers Squibb Company
16.9. Cipla Limited
16.10. Dr. Reddy’s Laboratories Ltd.
16.11. Eli Lilly and Company
16.12. Gilead Sciences, Inc.
16.13. GlaxoSmithKline plc
16.14. Hetero Labs Limited
16.15. Johnson & Johnson
16.16. Laurus Labs Limited
16.17. Lupin Limited
16.18. Merck & Co., Inc.
16.19. Natco Pharma Limited
16.20. Novartis AG
16.21. Pfizer Inc.
16.22. Pharco Pharmaceuticals
16.23. Regeneron Pharmaceuticals, Inc.
16.24. Roche Holding AG
16.25. Sanofi S.A.
16.26. Strides Pharma Science Limited
16.27. Takeda Pharmaceutical Company Limited
16.28. Teva Pharmaceutical Industries Ltd.
16.29. Vertex Pharmaceuticals Incorporated
16.30. Viatris Inc.
16.31. Zydus Lifesciences Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Direct Acting Antivirals Market, Years Considered for the Study
FIGURE 2. Global Direct Acting Antivirals Market, Research Design
FIGURE 3. Global Direct Acting Antivirals Market, Research Framework
FIGURE 4. Global Direct Acting Antivirals Market, Data Triangulation
FIGURE 5. Global Direct Acting Antivirals Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Direct Acting Antivirals Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Direct Acting Antivirals Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Direct Acting Antivirals Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Direct Acting Antivirals Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Direct Acting Antivirals Market Size, by Treatment Regimen, 2025 vs 2032 (%)
FIGURE 11. Global Direct Acting Antivirals Market Size, by Treatment Regimen, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Direct Acting Antivirals Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Direct Acting Antivirals Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Direct Acting Antivirals Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Direct Acting Antivirals Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Direct Acting Antivirals Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Direct Acting Antivirals Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Direct Acting Antivirals Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Direct Acting Antivirals Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Direct Acting Antivirals Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Direct Acting Antivirals Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Direct Acting Antivirals Market Segmentation & Coverage
TABLE 2. Global Direct Acting Antivirals Market Size, 2017-2032 (USD Million)
TABLE 3. Global Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Ns3/4A Protease Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Ns3/4A Protease Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Ns3/4A Protease Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Glecaprevir Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Glecaprevir Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Glecaprevir Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Voxilaprevir Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Voxilaprevir Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Voxilaprevir Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Ns5A Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Ns5A Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Ns5A Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Ledipasvir Sofosbuvir Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Ledipasvir Sofosbuvir Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Ledipasvir Sofosbuvir Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Velpatasvir Sofosbuvir Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Velpatasvir Sofosbuvir Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Velpatasvir Sofosbuvir Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Ns5B Polymerase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Ns5B Polymerase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Ns5B Polymerase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Dasabuvir Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Dasabuvir Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Dasabuvir Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Sofosbuvir Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Sofosbuvir Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Sofosbuvir Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 32. Global Fixed Dose Combinations Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Fixed Dose Combinations Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Fixed Dose Combinations Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Once Daily Dosing Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Once Daily Dosing Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Once Daily Dosing Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Twice Daily Dosing Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Twice Daily Dosing Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Twice Daily Dosing Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Single Agent Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Single Agent Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Single Agent Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Once Daily Dosing Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Once Daily Dosing Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Once Daily Dosing Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Twice Daily Dosing Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Twice Daily Dosing Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Twice Daily Dosing Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Direct Acting Antivirals Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 51. Global Combination Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Combination Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Combination Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Dual Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Dual Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Dual Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Ns3 4A Ns5A Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Ns3 4A Ns5A Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Ns3 4A Ns5A Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Ns5A Ns5B Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Ns5A Ns5B Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Ns5A Ns5B Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Triple Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Triple Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Triple Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Monotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Monotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Monotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Direct Acting Antivirals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 70. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Direct Acting Antivirals Market Size, by End User, 2017-2032 (USD Million)
TABLE 80. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Direct Acting Antivirals Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Asia-Pacific Direct Acting Antivirals Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Asia-Pacific Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific Direct Acting Antivirals Market Size, by Ns3/4A Protease Inhibitors, 2017-2032 (USD Million)
TABLE 93. Asia-Pacific Direct Acting Antivirals Market Size, by Ns5A Inhibitors, 2017-2032 (USD Million)
TABLE 94. Asia-Pacific Direct Acting Antivirals Market Size, by Ns5B Polymerase Inhibitors, 2017-2032 (USD Million)
TABLE 95. Asia-Pacific Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 96. Asia-Pacific Direct Acting Antivirals Market Size, by Fixed Dose Combinations, 2017-2032 (USD Million)
TABLE 97. Asia-Pacific Direct Acting Antivirals Market Size, by Single Agent Tablets, 2017-2032 (USD Million)
TABLE 98. Asia-Pacific Direct Acting Antivirals Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 99. Asia-Pacific Direct Acting Antivirals Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 100. Asia-Pacific Direct Acting Antivirals Market Size, by Dual Therapy, 2017-2032 (USD Million)
TABLE 101. Asia-Pacific Direct Acting Antivirals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 102. Asia-Pacific Direct Acting Antivirals Market Size, by End User, 2017-2032 (USD Million)
TABLE 103. North America Direct Acting Antivirals Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. North America Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 105. North America Direct Acting Antivirals Market Size, by Ns3/4A Protease Inhibitors, 2017-2032 (USD Million)
TABLE 106. North America Direct Acting Antivirals Market Size, by Ns5A Inhibitors, 2017-2032 (USD Million)
TABLE 107. North America Direct Acting Antivirals Market Size, by Ns5B Polymerase Inhibitors, 2017-2032 (USD Million)
TABLE 108. North America Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 109. North America Direct Acting Antivirals Market Size, by Fixed Dose Combinations, 2017-2032 (USD Million)
TABLE 110. North America Direct Acting Antivirals Market Size, by Single Agent Tablets, 2017-2032 (USD Million)
TABLE 111. North America Direct Acting Antivirals Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 112. North America Direct Acting Antivirals Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 113. North America Direct Acting Antivirals Market Size, by Dual Therapy, 2017-2032 (USD Million)
TABLE 114. North America Direct Acting Antivirals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 115. North America Direct Acting Antivirals Market Size, by End User, 2017-2032 (USD Million)
TABLE 116. Latin America Direct Acting Antivirals Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Latin America Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 118. Latin America Direct Acting Antivirals Market Size, by Ns3/4A Protease Inhibitors, 2017-2032 (USD Million)
TABLE 119. Latin America Direct Acting Antivirals Market Size, by Ns5A Inhibitors, 2017-2032 (USD Million)
TABLE 120. Latin America Direct Acting Antivirals Market Size, by Ns5B Polymerase Inhibitors, 2017-2032 (USD Million)
TABLE 121. Latin America Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 122. Latin America Direct Acting Antivirals Market Size, by Fixed Dose Combinations, 2017-2032 (USD Million)
TABLE 123. Latin America Direct Acting Antivirals Market Size, by Single Agent Tablets, 2017-2032 (USD Million)
TABLE 124. Latin America Direct Acting Antivirals Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 125. Latin America Direct Acting Antivirals Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 126. Latin America Direct Acting Antivirals Market Size, by Dual Therapy, 2017-2032 (USD Million)
TABLE 127. Latin America Direct Acting Antivirals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 128. Latin America Direct Acting Antivirals Market Size, by End User, 2017-2032 (USD Million)
TABLE 129. Europe Direct Acting Antivirals Market Size, by Region, 2017-2032 (USD Million)
TABLE 130. Europe Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 131. Europe Direct Acting Antivirals Market Size, by Ns3/4A Protease Inhibitors, 2017-2032 (USD Million)
TABLE 132. Europe Direct Acting Antivirals Market Size, by Ns5A Inhibitors, 2017-2032 (USD Million)
TABLE 133. Europe Direct Acting Antivirals Market Size, by Ns5B Polymerase Inhibitors, 2017-2032 (USD Million)
TABLE 134. Europe Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 135. Europe Direct Acting Antivirals Market Size, by Fixed Dose Combinations, 2017-2032 (USD Million)
TABLE 136. Europe Direct Acting Antivirals Market Size, by Single Agent Tablets, 2017-2032 (USD Million)
TABLE 137. Europe Direct Acting Antivirals Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 138. Europe Direct Acting Antivirals Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 139. Europe Direct Acting Antivirals Market Size, by Dual Therapy, 2017-2032 (USD Million)
TABLE 140. Europe Direct Acting Antivirals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 141. Europe Direct Acting Antivirals Market Size, by End User, 2017-2032 (USD Million)
TABLE 142. Middle East Direct Acting Antivirals Market Size, by Region, 2017-2032 (USD Million)
TABLE 143. Middle East Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 144. Middle East Direct Acting Antivirals Market Size, by Ns3/4A Protease Inhibitors, 2017-2032 (USD Million)
TABLE 145. Middle East Direct Acting Antivirals Market Size, by Ns5A Inhibitors, 2017-2032 (USD Million)
TABLE 146. Middle East Direct Acting Antivirals Market Size, by Ns5B Polymerase Inhibitors, 2017-2032 (USD Million)
TABLE 147. Middle East Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 148. Middle East Direct Acting Antivirals Market Size, by Fixed Dose Combinations, 2017-2032 (USD Million)
TABLE 149. Middle East Direct Acting Antivirals Market Size, by Single Agent Tablets, 2017-2032 (USD Million)
TABLE 150. Middle East Direct Acting Antivirals Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 151. Middle East Direct Acting Antivirals Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 152. Middle East Direct Acting Antivirals Market Size, by Dual Therapy, 2017-2032 (USD Million)
TABLE 153. Middle East Direct Acting Antivirals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 154. Middle East Direct Acting Antivirals Market Size, by End User, 2017-2032 (USD Million)
TABLE 155. Africa Direct Acting Antivirals Market Size, by Region, 2017-2032 (USD Million)
TABLE 156. Africa Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 157. Africa Direct Acting Antivirals Market Size, by Ns3/4A Protease Inhibitors, 2017-2032 (USD Million)
TABLE 158. Africa Direct Acting Antivirals Market Size, by Ns5A Inhibitors, 2017-2032 (USD Million)
TABLE 159. Africa Direct Acting Antivirals Market Size, by Ns5B Polymerase Inhibitors, 2017-2032 (USD Million)
TABLE 160. Africa Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 161. Africa Direct Acting Antivirals Market Size, by Fixed Dose Combinations, 2017-2032 (USD Million)
TABLE 162. Africa Direct Acting Antivirals Market Size, by Single Agent Tablets, 2017-2032 (USD Million)
TABLE 163. Africa Direct Acting Antivirals Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 164. Africa Direct Acting Antivirals Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 165. Africa Direct Acting Antivirals Market Size, by Dual Therapy, 2017-2032 (USD Million)
TABLE 166. Africa Direct Acting Antivirals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 167. Africa Direct Acting Antivirals Market Size, by End User, 2017-2032 (USD Million)
TABLE 168. Global Direct Acting Antivirals Market Size, by Group, 2017-2032 (USD Million)
TABLE 169. ASEAN Direct Acting Antivirals Market Size, by Group, 2017-2032 (USD Million)
TABLE 170. ASEAN Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 171. ASEAN Direct Acting Antivirals Market Size, by Ns3/4A Protease Inhibitors, 2017-2032 (USD Million)
TABLE 172. ASEAN Direct Acting Antivirals Market Size, by Ns5A Inhibitors, 2017-2032 (USD Million)
TABLE 173. ASEAN Direct Acting Antivirals Market Size, by Ns5B Polymerase Inhibitors, 2017-2032 (USD Million)
TABLE 174. ASEAN Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 175. ASEAN Direct Acting Antivirals Market Size, by Fixed Dose Combinations, 2017-2032 (USD Million)
TABLE 176. ASEAN Direct Acting Antivirals Market Size, by Single Agent Tablets, 2017-2032 (USD Million)
TABLE 177. ASEAN Direct Acting Antivirals Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 178. ASEAN Direct Acting Antivirals Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 179. ASEAN Direct Acting Antivirals Market Size, by Dual Therapy, 2017-2032 (USD Million)
TABLE 180. ASEAN Direct Acting Antivirals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 181. ASEAN Direct Acting Antivirals Market Size, by End User, 2017-2032 (USD Million)
TABLE 182. GCC Direct Acting Antivirals Market Size, by Group, 2017-2032 (USD Million)
TABLE 183. GCC Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 184. GCC Direct Acting Antivirals Market Size, by Ns3/4A Protease Inhibitors, 2017-2032 (USD Million)
TABLE 185. GCC Direct Acting Antivirals Market Size, by Ns5A Inhibitors, 2017-2032 (USD Million)
TABLE 186. GCC Direct Acting Antivirals Market Size, by Ns5B Polymerase Inhibitors, 2017-2032 (USD Million)
TABLE 187. GCC Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 188. GCC Direct Acting Antivirals Market Size, by Fixed Dose Combinations, 2017-2032 (USD Million)
TABLE 189. GCC Direct Acting Antivirals Market Size, by Single Agent Tablets, 2017-2032 (USD Million)
TABLE 190. GCC Direct Acting Antivirals Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 191. GCC Direct Acting Antivirals Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 192. GCC Direct Acting Antivirals Market Size, by Dual Therapy, 2017-2032 (USD Million)
TABLE 193. GCC Direct Acting Antivirals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 194. GCC Direct Acting Antivirals Market Size, by End User, 2017-2032 (USD Million)
TABLE 195. European Union Direct Acting Antivirals Market Size, by Group, 2017-2032 (USD Million)
TABLE 196. European Union Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 197. European Union Direct Acting Antivirals Market Size, by Ns3/4A Protease Inhibitors, 2017-2032 (USD Million)
TABLE 198. European Union Direct Acting Antivirals Market Size, by Ns5A Inhibitors, 2017-2032 (USD Million)
TABLE 199. European Union Direct Acting Antivirals Market Size, by Ns5B Polymerase Inhibitors, 2017-2032 (USD Million)
TABLE 200. European Union Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 201. European Union Direct Acting Antivirals Market Size, by Fixed Dose Combinations, 2017-2032 (USD Million)
TABLE 202. European Union Direct Acting Antivirals Market Size, by Single Agent Tablets, 2017-2032 (USD Million)
TABLE 203. European Union Direct Acting Antivirals Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 204. European Union Direct Acting Antivirals Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 205. European Union Direct Acting Antivirals Market Size, by Dual Therapy, 2017-2032 (USD Million)
TABLE 206. European Union Direct Acting Antivirals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 207. European Union Direct Acting Antivirals Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. BRICS Direct Acting Antivirals Market Size, by Group, 2017-2032 (USD Million)
TABLE 209. BRICS Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 210. BRICS Direct Acting Antivirals Market Size, by Ns3/4A Protease Inhibitors, 2017-2032 (USD Million)
TABLE 211. BRICS Direct Acting Antivirals Market Size, by Ns5A Inhibitors, 2017-2032 (USD Million)
TABLE 212. BRICS Direct Acting Antivirals Market Size, by Ns5B Polymerase Inhibitors, 2017-2032 (USD Million)
TABLE 213. BRICS Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 214. BRICS Direct Acting Antivirals Market Size, by Fixed Dose Combinations, 2017-2032 (USD Million)
TABLE 215. BRICS Direct Acting Antivirals Market Size, by Single Agent Tablets, 2017-2032 (USD Million)
TABLE 216. BRICS Direct Acting Antivirals Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 217. BRICS Direct Acting Antivirals Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 218. BRICS Direct Acting Antivirals Market Size, by Dual Therapy, 2017-2032 (USD Million)
TABLE 219. BRICS Direct Acting Antivirals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 220. BRICS Direct Acting Antivirals Market Size, by End User, 2017-2032 (USD Million)
TABLE 221. G7 Direct Acting Antivirals Market Size, by Group, 2017-2032 (USD Million)
TABLE 222. G7 Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 223. G7 Direct Acting Antivirals Market Size, by Ns3/4A Protease Inhibitors, 2017-2032 (USD Million)
TABLE 224. G7 Direct Acting Antivirals Market Size, by Ns5A Inhibitors, 2017-2032 (USD Million)
TABLE 225. G7 Direct Acting Antivirals Market Size, by Ns5B Polymerase Inhibitors, 2017-2032 (USD Million)
TABLE 226. G7 Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 227. G7 Direct Acting Antivirals Market Size, by Fixed Dose Combinations, 2017-2032 (USD Million)
TABLE 228. G7 Direct Acting Antivirals Market Size, by Single Agent Tablets, 2017-2032 (USD Million)
TABLE 229. G7 Direct Acting Antivirals Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 230. G7 Direct Acting Antivirals Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 231. G7 Direct Acting Antivirals Market Size, by Dual Therapy, 2017-2032 (USD Million)
TABLE 232. G7 Direct Acting Antivirals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 233. G7 Direct Acting Antivirals Market Size, by End User, 2017-2032 (USD Million)
TABLE 234. NATO Direct Acting Antivirals Market Size, by Group, 2017-2032 (USD Million)
TABLE 235. NATO Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 236. NATO Direct Acting Antivirals Market Size, by Ns3/4A Protease Inhibitors, 2017-2032 (USD Million)
TABLE 237. NATO Direct Acting Antivirals Market Size, by Ns5A Inhibitors, 2017-2032 (USD Million)
TABLE 238. NATO Direct Acting Antivirals Market Size, by Ns5B Polymerase Inhibitors, 2017-2032 (USD Million)
TABLE 239. NATO Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 240. NATO Direct Acting Antivirals Market Size, by Fixed Dose Combinations, 2017-2032 (USD Million)
TABLE 241. NATO Direct Acting Antivirals Market Size, by Single Agent Tablets, 2017-2032 (USD Million)
TABLE 242. NATO Direct Acting Antivirals Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 243. NATO Direct Acting Antivirals Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 244. NATO Direct Acting Antivirals Market Size, by Dual Therapy, 2017-2032 (USD Million)
TABLE 245. NATO Direct Acting Antivirals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 246. NATO Direct Acting Antivirals Market Size, by End User, 2017-2032 (USD Million)
TABLE 247. Global Direct Acting Antivirals Market Size, by Country, 2017-2032 (USD Million)
TABLE 248. United States Direct Acting Antivirals Market Size, 2017-2032 (USD Million)
TABLE 249. United States Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 250. United States Direct Acting Antivirals Market Size, by Ns3/4A Protease Inhibitors, 2017-2032 (USD Million)
TABLE 251. United States Direct Acting Antivirals Market Size, by Ns5A Inhibitors, 2017-2032 (USD Million)
TABLE 252. United States Direct Acting Antivirals Market Size, by Ns5B Polymerase Inhibitors, 2017-2032 (USD Million)
TABLE 253. United States Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 254. United States Direct Acting Antivirals Market Size, by Fixed Dose Combinations, 2017-2032 (USD Million)
TABLE 255. United States Direct Acting Antivirals Market Size, by Single Agent Tablets, 2017-2032 (USD Million)
TABLE 256. United States Direct Acting Antivirals Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 257. United States Direct Acting Antivirals Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 258. United States Direct Acting Antivirals Market Size, by Dual Therapy, 2017-2032 (USD Million)
TABLE 259. United States Direct Acting Antivirals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 260. United States Direct Acting Antivirals Market Size, by End User, 2017-2032 (USD Million)
TABLE 261. Canada Direct Acting Antivirals Market Size, 2017-2032 (USD Million)
TABLE 262. Canada Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 263. Canada Direct Acting Antivirals Market Size, by Ns3/4A Protease Inhibitors, 2017-2032 (USD Million)
TABLE 264. Canada Direct Acting Antivirals Market Size, by Ns5A Inhibitors, 2017-2032 (USD Million)
TABLE 265. Canada Direct Acting Antivirals Market Size, by Ns5B Polymerase Inhibitors, 2017-2032 (USD Million)
TABLE 266. Canada Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 267. Canada Direct Acting Antivirals Market Size, by Fixed Dose Combinations, 2017-2032 (USD Million)
TABLE 268. Canada Direct Acting Antivirals Market Size, by Single Agent Tablets, 2017-2032 (USD Million)
TABLE 269. Canada Direct Acting Antivirals Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 270. Canada Direct Acting Antivirals Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 271. Canada Direct Acting Antivirals Market Size, by Dual Therapy, 2017-2032 (USD Million)
TABLE 272. Canada Direct Acting Antivirals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 273. Canada Direct Acting Antivirals Market Size, by End User, 2017-2032 (USD Million)
TABLE 274. Mexico Direct Acting Antivirals Market Size, 2017-2032 (USD Million)
TABLE 275. Mexico Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 276. Mexico Direct Acting Antivirals Market Size, by Ns3/4A Protease Inhibitors, 2017-2032 (USD Million)
TABLE 277. Mexico Direct Acting Antivirals Market Size, by Ns5A Inhibitors, 2017-2032 (USD Million)
TABLE 278. Mexico Direct Acting Antivirals Market Size, by Ns5B Polymerase Inhibitors, 2017-2032 (USD Million)
TABLE 279. Mexico Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 280. Mexico Direct Acting Antivirals Market Size, by Fixed Dose Combinations, 2017-2032 (USD Million)
TABLE 281. Mexico Direct Acting Antivirals Market Size, by Single Agent Tablets, 2017-2032 (USD Million)
TABLE 282. Mexico Direct Acting Antivirals Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 283. Mexico Direct Acting Antivirals Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 284. Mexico Direct Acting Antivirals Market Size, by Dual Therapy, 2017-2032 (USD Million)
TABLE 285. Mexico Direct Acting Antivirals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 286. Mexico Direct Acting Antivirals Market Size, by End User, 2017-2032 (USD Million)
TABLE 287. Brazil Direct Acting Antivirals Market Size, 2017-2032 (USD Million)
TABLE 288. Brazil Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 289. Brazil Direct Acting Antivirals Market Size, by Ns3/4A Protease Inhibitors, 2017-2032 (USD Million)
TABLE 290. Brazil Direct Acting Antivirals Market Size, by Ns5A Inhibitors, 2017-2032 (USD Million)
TABLE 291. Brazil Direct Acting Antivirals Market Size, by Ns5B Polymerase Inhibitors, 2017-2032 (USD Million)
TABLE 292. Brazil Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 293. Brazil Direct Acting Antivirals Market Size, by Fixed Dose Combinations, 2017-2032 (USD Million)
TABLE 294. Brazil Direct Acting Antivirals Market Size, by Single Agent Tablets, 2017-2032 (USD Million)
TABLE 295. Brazil Direct Acting Antivirals Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 296. Brazil Direct Acting Antivirals Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 297. Brazil Direct Acting Antivirals Market Size, by Dual Therapy, 2017-2032 (USD Million)
TABLE 298. Brazil Direct Acting Antivirals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 299. Brazil Direct Acting Antivirals Market Size, by End User, 2017-2032 (USD Million)
TABLE 300. United Kingdom Direct Acting Antivirals Market Size, 2017-2032 (USD Million)
TABLE 301. United Kingdom Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 302. United Kingdom Direct Acting Antivirals Market Size, by Ns3/4A Protease Inhibitors, 2017-2032 (USD Million)
TABLE 303. United Kingdom Direct Acting Antivirals Market Size, by Ns5A Inhibitors, 2017-2032 (USD Million)
TABLE 304. United Kingdom Direct Acting Antivirals Market Size, by Ns5B Polymerase Inhibitors, 2017-2032 (USD Million)
TABLE 305. United Kingdom Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 306. United Kingdom Direct Acting Antivirals Market Size, by Fixed Dose Combinations, 2017-2032 (USD Million)
TABLE 307. United Kingdom Direct Acting Antivirals Market Size, by Single Agent Tablets, 2017-2032 (USD Million)
TABLE 308. United Kingdom Direct Acting Antivirals Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 309. United Kingdom Direct Acting Antivirals Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 310. United Kingdom Direct Acting Antivirals Market Size, by Dual Therapy, 2017-2032 (USD Million)
TABLE 311. United Kingdom Direct Acting Antivirals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 312. United Kingdom Direct Acting Antivirals Market Size, by End User, 2017-2032 (USD Million)
TABLE 313. Germany Direct Acting Antivirals Market Size, 2017-2032 (USD Million)
TABLE 314. Germany Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 315. Germany Direct Acting Antivirals Market Size, by Ns3/4A Protease Inhibitors, 2017-2032 (USD Million)
TABLE 316. Germany Direct Acting Antivirals Market Size, by Ns5A Inhibitors, 2017-2032 (USD Million)
TABLE 317. Germany Direct Acting Antivirals Market Size, by Ns5B Polymerase Inhibitors, 2017-2032 (USD Million)
TABLE 318. Germany Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 319. Germany Direct Acting Antivirals Market Size, by Fixed Dose Combinations, 2017-2032 (USD Million)
TABLE 320. Germany Direct Acting Antivirals Market Size, by Single Agent Tablets, 2017-2032 (USD Million)
TABLE 321. Germany Direct Acting Antivirals Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 322. Germany Direct Acting Antivirals Market Size, by Combination Therapy, 2017-2032 (USD Million)
TABLE 323. Germany Direct Acting Antivirals Market Size, by Dual Therapy, 2017-2032 (USD Million)
TABLE 324. Germany Direct Acting Antivirals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 325. Germany Direct Acting Antivirals Market Size, by End User, 2017-2032 (USD Million)
TABLE 326. France Direct Acting Antivirals Market Size, 2017-2032 (USD Million)
TABLE 327. France Direct Acting Antivirals Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 328. France Direct Acting Antivirals Market Size, by Ns3/4A Protease Inhibitors, 2017-2032 (USD Million)
TABLE 329. France Direct Acting Antivirals Market Size, by Ns5A Inhibitors, 2017-2032 (USD Million)
TABLE 330. France Direct Acting Antivirals Market Size, by Ns5B Polymerase Inhibitors, 2017-2032 (USD Million)
TABLE 331. France Direct Acting Antivirals Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 332. France Direct Acting Antivirals Market Size, by Fixed Dose Combinations, 2017-2032 (USD Million)
TABLE 333. France Direct Acting Antivirals Market Size, by Single Agent Tablets, 2017-2032 (USD Million)
TABLE 334. France Direct Acting Antivirals

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Johnson & Johnson
  • Laurus Labs Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Natco Pharma Limited
  • Novartis AG
  • Pfizer Inc.
  • Pharco Pharmaceuticals
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Strides Pharma Science Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
  • Zydus Lifesciences Limited

Related Topics

Related Reports

Direct-acting Antiviral Drug Market - Global Forecast 2026-2032 - Product Image

Direct-acting Antiviral Drug Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Antiviral Drugs for the Treatment of Hepatitis C Market - Global Forecast 2026-2032 - Product Image

Antiviral Drugs for the Treatment of Hepatitis C Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 180 Pages
  • Global
From
Hepatitis Therapeutics - Global Strategic Business Report - Product Image

Hepatitis Therapeutics - Global Strategic Business Report

  • Report
  • 298 Pages
  • Global
From
Hepatitis Drugs Market Report 2026 - Product Image

Hepatitis Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.